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Ochratoxin A (OTA) exposure via ingestion and inhalation has been described in the literature to cause kidney disease in both
animals and humans. This paper reviews Ochratoxin A and its relationship to human health and kidney disease with a focus
on a possible association with focal segmental glomerulosclerosis (FSGS) in humans. Prevention and treatment strategies for
OTA-induced illness are also discussed, including cholestyramine, a bile-acid-binding resin used as a sequestrant to reduce the
enterohepatic recirculation of OTA.
1.Introduction
Ochratoxin A (OTA) is a known nephrotoxic, immunotoxic,
and carcinogenic mycotoxin in animals [1, 2] that has long
been studied for its role in animal and human disease. Molds
associated with the production of OTA include Aspergillus
ochraceus, Aspergillus niger and Aspergillus carbonarius, Peni-
cillium verrucosum, and species of Penicillium, Petromyces,
and Neopetromyces [3]. Concerns regarding exposure to
ochratoxin have primarily centered on exposure to food
contaminatedwithOTAsuchaswine,beer,coﬀee,driedvine
f r u i t ,g r a p ej u i c e s ,p o r k ,p o u l t r y ,d a i r y ,s p i c e s ,a n dc h o c o l a t e
[1]. Toxicity from ochratoxin is considered serious enough
that it is among approximately 20 mycotoxins monitored in
food.
Options for diagnosis and treatment of persons diag-
nosed with chronic kidney disease and FSGS are reviewed.
Treatment is then discussed in the context of two patients
diagnosed with FSGS who were found to have signiﬁcantly
elevated levels of urine OTA. This exposure is believed to
have resulted from inhalational exposure from water dam-
aged indoor environments found to have elevated levels of
mold including species of Aspergillus and Penicillium. This
review is intended to highlight the importance of prevention
and treatment of human kidney disease and ochratoxin
exposure from indoor mold.
2. Mechanismsof Toxicity
Ochratoxins occur in nature as Ochratoxin A, B, and C.
OTA is the most prevalent toxin, and our discussion will
be limited to OTA. OTA is a proven carcinogen in animals
and is classiﬁed as a class 2B, possible human carcinogen by
the International Agency for Research on Cancer [4]. The
National Toxicology Program (NTP) has designated OTA as
“reasonably anticipated to be a human carcinogen” based
on suﬃcient evidence of carcinogenicity in experimental
animals [1].
After initial exposure from any source, the urinary and
fecal excretory routes of OTA are both important with the
relative contribution of each dependent upon factors such
as route of administration and dose [5]. In the blood, OTA
binds to albumin and the bound fraction constitutes a
mobile reserve of OTA [6]. The relative contribution of each
excretory route is inﬂuenced by the degree of serum macro-
molecular binding as well as diﬀerences in the enterohepatic2 Journal of Environmental and Public Health
recirculation of OTA [7]. Elimination of OTA in urine and
feces is felt to be relatively slow and has been shown to vary
by species and gender as well as speciﬁc genotype that may
aﬀect the biotransformation of OTA [8, 9].
Intestinal microﬂora also appear to contribute signif-
icantly to the metabolism of OTA via hydrolyzation to
the less toxic ochratoxin alpha in rats [10]. Inhibition of
microﬂora in the lower GI tract of rats by neomycin results
in decreased hydrolysis of OTA to ochratoxin alpha resulting
in elevated levels of OTA [11]. In addition, administration of
radiolabeled OTA to rats indicated that eﬀective metabolism
of OTA was lacking in most tissues other than the intestines
[12]. The importance of digestion in the detoxication of
OTA is also supported by the observation that OTA does not
readily accumulate in ruminants due to rapid detoxiﬁcation
in the extensive ruminant stomach [5, 13].
Limited information is available on the metabolic dispo-
sition of OTA in humans, although it has been suggested that
it has a long serum half-life due to strong binding to human
serum macromolecules [7, 14].
Individual genetic diﬀerences aﬀect the biotransforma-
tion and relative toxicity of OTA, with enzymatic hydrolysis
and cytochrome p450 induction felt to play a role in toxicity.
Studies have indicated that the biotransformation of OTA
can be eﬀected by CYP 3A4, CYP 1A1, and CYP 2C9-1 while
conﬂicting results have been found for CYP 1A2 [15, 16].
DNAadductsalsooccurinanimalsexposedtoOTAinall
available studies [17–20]. DNA adducts consist of a chemical
covalentlyboundtoDNA.ThiscouldinterferewiththeDNA
repair systems and cell cycle controls systems and serve as an
initiating point of carcinogenesis.
Oxidative stress is another component of OTA toxicity
[21]. Pretreatment of rats with retinol (vitamin A), ascorbic
acid (vitamin C), or alpha tocopherol (vitamin E) before
OTA administration signiﬁcantly decreased the number of
DNA adducts formed in the kidney by 70 percent, 90
percent, and 80 percent, respectively [22]. In addition, lipid
peroxidation and enzymes involved in arachidonic acid
metabolism aﬀect the biotransformation of OTA [23].
More recently, it is been shown in rodents that
mTOR/AKT pathways are signiﬁcantly deregulated after
exposure to OTA, possibly contributing to carcinogenicity in
kidney cells [24].
3. Tissue Distribution
Tissue distribution after exposure of animals to OTA has
consistently revealed that the greatest concentration is in
the kidneys followed by either liver or muscle and then
fat [25–27], but tissues found to contain OTA also include
the adrenal medulla and cortex, skin, myocardium, gastric
mucosa, and bone marrow [28].
In humans, OTA has been detected in blood, urine, and
breast milk [29–31]a sw e l la sr e n a lc e l lc a r c i n o m a s ,b r e a s t
cancer,astrocytoma,inﬂamedbladdertissueandtransitional
cell carcinoma of the bladder, and a skin biopsy sample [32].
R e c e n t l y ,ac a s eh a sb e e nr e p o r t e do fO T Ab e i n gf o u n di n
the umbilical cord and placental tissue of a newborn whose
mother had been exposed from a water-damaged home. In
addition, the mother had OTA in her breast milk, urine,
and nasal secretions [33]. Also, other family members tested
positive for OTA in urine and nasal secretion samples, while
the pet dog was positive for OTA in its urine and an ear mass
[33].
4. Agents ModulatingToxicity
Various substances have been found to either increase or
decrease the toxicity of OTA. In mice, pretreatment with
phenobarbital decreased the toxicity of OTA with signiﬁcant
increases in LD50 seen [34, 35]. Administration of piperonyl
butoxide was also shown to signiﬁcantly decrease the LD50
of OTA [35] thus increasing toxicity.
Ap r o t e c t i v ee ﬀect of melatonin and licorice plant extract
w a sd e m o n s t r a t e di nr a t se x p o s e dt oO T Af o r2 8d a y sa n d
alleviated most of the biochemical abnormalities associated
with the exposure [36]. It is signiﬁcant in this study that the
histopathological abnormalities were seen in this relatively
short 28 day exposure and showed degenerative symptoms
in the proximal tubules, congestion in renal tissue, and a
remarkable inﬁltration of inﬂammatory cells consistent with
OTA nephropathy.
Phenylalanine prevents acute poisoning by OTA in mice
[37]. Aspartame, a structural analogue of phenylalanine, is
also a powerful inhibitor of OTA toxicity, at least in animals
[38].
In male rats, OTA was more toxic in the pres-
ence of phenylbutazone (a nonsteroidal anti inﬂammatory
drug/NSAID) and ethyl biscoumacetate (vitamin K antago-
nist/coumarin) and was less toxic when administered with
sulfamethoxypridazine (a sulfonamide antibiotic) [39].
5. Exposureto OchratoxinA from Food
Dietary exposure to OTA has been extensively documented
in the literature and worldwide remains a signiﬁcant source
of OTA exposure in humans [1, 4]. Background studies
on average levels of OTA in humans eating a typical diet
have,however,onlyshownmodestelevationsinurinaryOTA
levels, well under the 2.0ppb limit of detection level used by
the commercial lab to test these patients [40].
6. InhalationalExposureto OchratoxinA
Throughout the literature, much of the study of ochratoxin
exposure focuses on exposure through ingestion. However,
inhalation exposure in water-damaged buildings with ampli-
ﬁed indoor growth of ochratoxin producing species of mold
remains a signiﬁcant risk. OTA has been identiﬁed in studies
of water-damaged buildings from air [41], dust [42], wallpa-
per [43], and agricultural dust and conidia [44]. Hooper et
al.havereported elevatedconcentrationsofOTAinthe urine
of individuals exposed to water-damaged buildings versus
unexposed controls [40]. The concentrations of mycotoxins
for controls not exposed to water damaged buildings were
below the detection limit which is 2.0ppb for ochratoxin
[40].Journal of Environmental and Public Health 3
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collected from three Norwegian cowsheds [44]. OTA was
detected in 6 out of 14 samples with concentrations ranging
f r o m0 . 2t o7 0μg/kg (ppb) [44]. Collected conidia also con-
tained OTA. The authors concluded that airborne dust and
conidia can be sources of OTA and that peak exposures and
absorptions from this route can be considerable, especially
given the eﬃciency with which OTA is absorbed through the
lung [44, 45]. Testing has also indicated the presence of OTA
from samples of air ﬁlters, refrigerator ﬁlters, dust from air
vents,andatowelandsandalsfromwater-damagedbuildings
[32, 33].
In another study of dust collected from heating ducts
in a household where animals were exhibiting signs of
ochratoxin poisoning, it was found that all samples in one
group yielded ochratoxin, with samples from one duct being
over 1500ppb and another duct showing levels of 306ppb.
In a sample group in the same study, the dust from six
samples was measured in a composite showing a level of
58ppb [42]. In a subsequent study using high-performance
liquid chromatography to quantify airborne mycotoxins in
a poultry house in Dalian, China, OTA along with aﬂatoxin
and zearalenone was detected [41].
Rapid systemic appearance of OTA after inhalation
exposure in rats has been documented with a 98 percent
bioavailability [45]. This clearly makes inhalational exposure
to OTA a very signiﬁcant risk.
One of the most striking cases documented in the
literature involves the onset of acute renal failure from
inhaled OTA after an 8-hour exposure to a granary that
had been closed for several years in which an ochratoxin-
producing strain of Aspergillus ochraceus was isolated [46].
The couple who were exposed to this granary experienced
respiratory distress, retrosternal burning, epigastric tension,
and asthenia. The husband’s condition improved within 24
hours; however, the women’s condition worsened and she
was admitted 5 days later with nonoliguric renal failure, pul-
monary edema, periorbital and lower extremity edema, and
proteinuria of 4.6g/L. A biopsy showed acute tubulonecrosis
with interstitial edema with localized inﬁltration of lym-
phocytes, granulocytes, and macrophages with thickening of
the basement membrane. Fortunately, her kidney function
returned to normal 40 days after the exposure.
7. OchratoxinandRenal Disease
Ochratoxin A has been found to be nephrotoxic in all
mammalian species treated [6], although diﬀerences in
toxicity have been found among species and sex. OTA is
excreted in both the stool and urine. Although likely a minor
route of excretion, ochratoxin has also been found in human
sweat [47].
OTA has been associated with human kidney disease
and is the probable causative agent of Balkan Endemic
Nephropathy (BEN) [48], a severe, progressive, and ulti-
mately fatal renal disease aﬀecting populations in the Balkan
Peninsula. Studies have indicated elevated levels of OTA in
persons aﬀected by BEN compared to neighboring persons
in unaﬀected Bulgarian villages [1]. Additionally, several
studies in animals have conﬁrmed a causal connection
betweenOTAexposureandcancersoftheurinarytract,liver,
and mammary glands [49–52]. Striking similarities have
been noted between OTA-induced porcine nephropathy in
pigs and BEN in humans [21].
The main nephrotoxic eﬀect is in the postproximal
nephron and proximal tubule which have been reported as
a self-enhancing eﬀect [53, 54].
A recent study in Sri Lanka measuring mycotoxin levels
in the urine of patients with kidney disease demonstrated
the presence of ochratoxin in 93.5 percent of patients tested
although ochratoxin was also found in individuals without
kidneydisease[55].Clark ’ sr eviewo foc hrat o xinintheblood
concluded that the highest levels were observed in sampled
populations that included persons with kidney disorders
with serum level as high as 35–100ng/mL (ppb) [1]. In
contrast, mean serum OTA level in Europe was found to be
0.1–2ng/mL (ppb) [1].
A correlation of consumption of foods known to contain
OTA and the incidence of testicular cancer in 20 countries
has suggested the possibility of OTA being related to an
increased incidence of testicular carcinoma. The authors also
report that there is correlation of pork and coﬀee intake
with testicular carcinoma. In addition, animals exposed to
OTA contain OTA in the testes and OTA causes adducts in
testicular DNA [56].
Several studies on Tunisians with and without renal
disease have shown elevations in serum OTA levels in both
populations, with higher levels being found in those with
renal disease. In one report, the mean value of OTA for
the healthy control population was 3.3 ± 1.5ng/mL (ppb)
compared to a mean value of 18 ± 7ng/mL (ppb) in
those with chronic interstitial nephropathy of unknown
origin [57]. Another study of OTA in human blood samples
comparing persons with various types of chronic kidney
disease to controls showed elevations in serum ochratoxin
which were greatest in those diagnosed with chronic inter-
stitial nephropathy at mean values of 25–59ng/mL (ppb)
compared to 0.7–7.8ng/mL (0.7–7.8 ppb) in the general
population and 6–18ng/mL (ppb) in those with other types
of kidney disease [58].
8. OchratoxinandReproduction
Ochratoxin can cross the placenta and has been found to be
embryotoxic in rats and mice [6]. Studies with radiolabeled
OTA in mice showed OTA to cross the placenta [59],
preferentially at speciﬁc times during gestation. Additionally
OTA has been found in breast milk which could represent a
signiﬁcant source of exposure for infants [33, 60].
A study of rats exposed to OTA preconception, during
gestation and during lactation showed that the exposed
oﬀspring had three to four times higher levels of OTA than
the controls. The rat oﬀspring exposed to OTA in both in
uteroandthroughbreastmilkwerefoundtohavethehighest
blood and kidney concentrations of OTA, with the most
signiﬁcantexposureattributedtolactation[60].Inthisstudy,
the transfer of OTA to breast milk was found to be very
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Moreover, a study in rabbits showed an eﬀective transport of
OTA from blood to milk and subsequently to the oﬀspring
with plasma and kidney concentrations much higher in
oﬀspring than adults, possibly due to slower detoxiﬁcation
in the oﬀspring [61]. A study involving 80 Norwegian
women found that 21 percent of the breast milk samples
showed elevations of OTA ranging from 10 to 182ng/L
(ppt) [62]. The authors believed that these observations were
very signiﬁcant since studies in neonatal rats have shown
that neonates are much more susceptible than adult rats
with LD50 values for OTA from the oral route being only
3.9mg/kg in neonates compared with adult LD 50 values of
20–330.3mg/kg in adults [5]. In addition, testing breast milk
samples from 75 women in Ankara, Turkey whose children
were patients in the Neonatology Department, showed OTA
in all samples tested in the range of 620.87–11311.30ng/L
(ppt) [63]. Additionally, OTA concentration in fetal serum
was reported to be twice that of the mother indicating an
active transfer of OTA across the placenta [64].
OTA was also shown to decrease testosterone secretion in
testicular interstitial cells of gerbils [65].
9.Ochratoxinandthe Brain
In vitro and in vivo research has demonstrated cerebellar [66,
67],hippocampal[68],andotheradverseneurologicaleﬀects
due to OTA [66–69]. A single dose of OTA to Swiss mice
was associated with signiﬁcant oxidative damage in six brain
regions—the cerebellum, hippocampus, caudate putamen,
pons medulla, substantia nigra, and cerebral cortex. Peak
eﬀects were observed in the midbrain, caudate/putamen,
and hippocampus [69]. In addition, striatal dopamine was
decreased after a single exposure to OTA [69]. In vitro
experiments have shown decreased proliferation of neural
progenitor stem cells in the hippocampal region of mice
after exposure to OTA leading the authors to speculate
that problems impairing hippocampal neurogenesis in vivo
could contribute to the memory problems and depression
commonly seen in humans exposed to mycotoxins [68]. In
another study evaluating the neurotoxicity of ochratoxin A,
primary neurons and neuronal cells were incubated with
increasing concentrations of OTA [66]. A dose-dependent
increase in cytotoxicity was found in both cell types resulting
from apoptosis and accompanied by a loss of mitochondrial
membrane potential [66]. Based on these data, the authors
speculated that OTA may contribute to the development of
neurodegenerative diseases such as Alzheimer’s and Parkin-
son’sinwhichapoptoticprocessesarecentrallyinvolved[66].
10.OchratoxinandImmunity
OTA is known to be immunotoxic in animal studies [1, 2,
70] .T h ei m m u n o s u p p r e s s a n ta c t i v i t yo fO T Ai na n i m a l sh a s
been characterized by size reduction of vital immune organs
like the thymus, spleen and lymph nodes, depression of
antibody responses, alterations in the number and functions
of immune cells, and modulation of cytokine production
[70].
There arealso complex relationships between Aspergillus,
T regulatory lymphocytes and candidiasis [71], which can be
clinically relevant in humans.
11. Focal Segmental Glomerulosclerosis (FSGS)
FSGS is a potentially devastating kidney disease that occurs
most frequently in children and young adults but can occur
at any age. In early stages of the disease, the kidneys are
typically normal or enlarged, while in the late stage of the
illness, kidneys are typically shrunken [72].
FSGS accounts for approximately one sixth of the cases
of nephrotic syndrome in children and is a common cause
of kidney failure in adults. The annual incidence of end-
stage renal disease from FSGS has increased 11-fold from 0.2
percent to 2.3 percent between 1980 and 2000, and FSGS
is now the most common cause of end-stage renal disease
resulting from primary glomerular disease [72].
There has been increasing recognition of causes in pri-
mary FSGS including genetic, viral, drug toxicity, and others.
Cases are considered primary with no cause identiﬁed or
secondary due to infections (HIV, Hep B, Parvovirus), toxins
(heroin, pamidronate, analgesics), familial, or nephron loss
from chronic pyelonephritis, obesity, diabetes, sickle cell
disease, or anatomic abnormalities and malignancies [71].
It is not uncommon for the onset of illness to occur after
an upper respiratory infection. Ethnic diﬀerences are seen in
the prevalence of the disease with blacks aﬀected seven times
more often as whites with a worse prognosis once the disease
is acquired [72].
Treatments for FSGS include salt and protein restriction,
diuretics for edema, ACE inhibitors, aldosterone antago-
nists, steroids, cytotoxics agents (e.g., cyclophosphamide),
immunosuppressants (e.g., cyclosporin and tacrolimus),
plasmapharesis, and treatment for hyperlipidemia which
commonly occurs with the illness [72]. Rarely intravenous
albumin or mannitol has been used for intractable edema.
Often no treatment is successful and the patient requires
dialysis and eventual transplantation. In patients who do not
respond to treatment, the average time from onset of the
disease to end-stage renal disease is from 6 to 8 years [72].
Recurrence of the disease posttransplantation has long
been recognized as a signiﬁcant risk. In one study of
77, mostly pediatric patients with idiopathic nephrotic
syndrome and FSGS who underwent transplantation, 42
had nephrotic range proteinuria posttransplant, and 20
eventually developed pathology consistent with FSGS in the
transplanted kidney [73]. Interestingly, the majority of the
recurrence occurs in the ﬁrst 6 months, with the recurrence
of illness rare after two years posttransplantation.
12.HumanFSGSandKidneyDiseaseAssociated
with OchratoxinA: PatientHistories
TwopatientshistoriesofFSGSassociatedwithOTAexposure
encountered by the authors are presented.
The ﬁrst patient was a 48-year-old woman diagnosed
with primary idiopathic FSGS who presented with end-
stage renal disease 10 days before a scheduled kidneyJournal of Environmental and Public Health 5
transplantation. She had been referred by her daughter’s
pediatricianaftersheexpressedconcernaboutherdaughter’s
serious respiratory symptoms and asthma exacerbations
and indicated that her home had recently been found to
have signiﬁcant mold contamination including elevations of
Aspergillus/Penicillium and Stachybotrys on nonviable spore
sampling. The most signiﬁcant elevations were found in the
room she had used as a home oﬃce. The patient worked as
a marriage and family therapist from her home oﬃce until
she was no longer able to work due to her illness. She moved
into the home 12 years prior to presentation and believes
the water damage to have been long standing, predating her
move. Shortly after moving into the home she developed
symptomsofchronicfatiguesyndromewhichhavepersisted.
Three and a half years before her presentation to the oﬃce,
she was seen in the emergency room for severe edema
and diagnosed with nephrotic syndrome. The diagnosis of
FSGS followed several kidney biopsies after it was initially
undetected. Attempts to control the disease with long-
term high-dose steroids were unsuccessful, and the disease
progressed to the point where she was placed on peritoneal
dialysis and the search for a donor kidney commenced. At
the time of presentation to this oﬃce she was taking vitamin
D, folic acid, dialyvite, calcitriol, sevelamer carbonate (a
phosphate binder), and rosuvastatin for hyperlipidemia.
Hyperlipidemia is a common complication of her type of
renal disease or nephrotic syndrome. Physical exam was
remarkable for a tired, uncomfortable appearing woman
who felt nauseated on several occasions during the exam.
She displayed 1+ pitting pretibial edema, mucosal nasal
swelling with white patches noted, a thick white coating on
her tongue, a I/VI systolic murmur which did not radiate,
and moderate dysmetria on ﬁnger to nose testing. Urine
mycotoxin testing was performed, and the patient was found
to have signiﬁcant elevations of ochratoxin A at 11.9ppb
(limit of detection 2.0ppb). Aﬂatoxin and trichothecene
mycotoxins were tested and were not detected. The testing
for ochratoxin A was performed by a CLIA certiﬁed lab
using immunoaﬃnity columns and ﬂuorometry [40]. The
patient reported a history of recurrent yeast infections
necessitating the use of oral ﬂuconazole and was found to
be anergic to candida on intradermal skin testing, with a
normal response to tetanus noted. A nasal fungal culture
showed the presence of Cladosporium species, while fungal
blood cultures remained negative. Testing for antibodies
to Aspergillus species of mold was recommended but not
performed.Priortothedietarychangesrequiredbytheonset
of renal failure, the patient’s diet was typical of the general
population and did not include excessive consumption of
foods known to contain OTA.
The patient was encouraged to commence treatment
with oral cholestyramine as soon as possible, but met with
resistance from her transplant team and ultimately did not
initiate therapy. She did, however, follow the recommen-
dation to move from her home to which she has not yet
returned and has avoided further exposure to items exposed
to the mold contaminated home. Her posttransplantation
course was remarkable for the recurrence of proteinuria
within days of the transplantation. Her function in the
transplanted kidney has continued to deteriorate, and she
was diagnosed with FSGS in the previously healthy donor
kidney within months of the transplantation. Additionally,
she has experienced rejection of the transplanted kidney
requiring a course of solumedrol and long-term use of
immunosuppressant agents. To date, the patient has not
undergone any treatment to reduce the body burden of
ochratoxin indicated by her initial elevations in urinary
ochratoxin other than avoidance of her water-damaged
home.
The second patient was a 5-year-old girl who presented
to the oﬃce with a history of receiving a diagnosis of
FSGS at the age of 3.5 after proteinuria was identiﬁed when
she presented to her pediatrician experiencing new onset
enuresis. The family sought care from the authors due to
chronic symptoms and illnesses in all family members and
history of exposure to water-damaged environments in past
and current homes. Due to the father’s work, the family has
moved frequently. They recall evidence of water damage and
mold in several of their previous homes and conﬁrmed the
presence of elevated levels of indoor mold in their current
home. The patient’s diet was typical for her age and did not
include excessive consumption of foods known to contain
elevated levels of ochratoxin.
Testing indicated the patient did not have a genetic cause
for FSGS. Upon diagnosis she was placed on a 6-week course
of high-dose prednisone and has since used tacrolimus and
enalaprilaswellasgalactose.H erproteinex cretioninurineis
followed regularly, and her mother reports an increased level
of proteinuria upon moving to their most recent home.
She was born by NSVD at 39 weeks gestation. APGAR
scores are not available. Her mother reports she required
some initial resuscitation, but improved quickly and did not
require transfer to neonatal intensive care unit. At 5 days of
age, she was found to have severe hyperbilirubinemia, with
reportedlevelsof26mg/dL.Shewasbreastfedfor14months.
Her physical exam was remarkable for nasal mucosal
swelling with clear discharge and erythematous right tym-
panic membrane consistent otitis media, slightly enlarged
bilateral submandibular lymph nodes, and moderate sway
when balancing on toes with eyes open and an inability to
balance on toes with eyes closed.
Urine mycotoxin testing was performed, and she was
found to have signiﬁcantly elevated level of ochratoxin
A at 9.1ppb (limit of detection 2.0ppb). Aﬂatoxin and
trichothecene mycotoxins were not detected in the sample.
Of note, elevations in urinary levels of ochratoxin and tri-
chothecene mycotoxins were found in other family members
aswouldbeexpectedwiththeirsharedinhalationalexposure;
however, the patient’s level of OTA was signiﬁcantly higher
than that of the other family members.
At the time of presentation to this oﬃce, the patient was
also reporting symptoms of night sweats, heat intolerance,
frequent episodes of otitis media and conjunctivitis, dizzi-
ness, hair loss, fungal skin rashes, episodes of excessive thirst,
and the recent onset of reversing letters when she writes.
Additionally, she has a history of signiﬁcant dental disease
including requiring a root canal at the age of 4.6 Journal of Environmental and Public Health
The patient was started on therapy including avoidance
of exposure to water-damaged/moldy environments and
property exposed to these environments and the use of
nutritional support, liposomal glutathione, and sequester-
ing agents including cholestyramine and charcoal. Within
months of starting treatment, the mother reported a signif-
icant decrease in the patients urinary protein excretion with
the lowest levels found to date on recent testing.
13. Treatment
Given the well-known nephrotoxicity of OTA, as well as
reports of human kidney disease associated with elevated
levels of OTA, including BEN and other kidney disease, and
this report of elevated OTA in two patients diagnosed with
FSGS, we believe it is appropriate to obtain a detailed clinical
history documenting potential exposures to water-damaged
buildings with elevated levels of mold as well as a dietary
history of persons diagnosed with FSGS and signiﬁcant renal
disease for which an alternative explanation is not readily
available. Since testing for mycotoxins in urine and other
tissuesisnowreadilyavailable[40],itisappropriatetoobtain
this testing on urine and renal biopsy tissue to help elucidate
whether this is a potential contributor to illness. In cases
where elevated levels of OTA and/or evidence of signiﬁcant
indoor water damage is found, urging avoidance of further
exposure would be strongly recommended. In addition, in
cases where the disease has progressed to the state where
kidney transplantation is indicated, knowing if the existing
kidneys have a signiﬁcant concentration of OTA might aﬀect
the decision about whether to leave the diseased kidneys in
place at the time of transplantation.
Various other means of lowering the renal burden of
OTA have been studied with varying degrees of success.
Most promising is the use of cholestyramine as a bile acid
resin binding agent to reduce enterohepatic recirculation
of OTA, thereby reducing levels that are ﬁltered through
the kidneys and shifting excretion to the stool where it is
presumably bound to cholestyramine resin. Cholestyramine
is not absorbed systemically allowing it to be safe even for
those with advanced kidney disease. Studies in rats showed
that OTA exposed rats that were fed a diet enriched with
cholestyramine experienced decreased OTA concentration
in plasma as well as decreased excretion of OTA and its
metabolites (ochratoxin alpha and hydroxylated ochratoxin
A) in bile and urine [74]. This was associated with an
increased excretion of OTA in feces which was felt to reduce
the potential nephrotoxicity of OTA.
StudiesofsweathaveshownthepresenceofOTAinsweat
on at least one occasion [47] supporting treatments such as
sauna to increase excretion of OTA.
Several studies have indicated that phenylalanine
decreases the absorption and consequent toxicity of OTA,
and this is also true of aspartame [34, 37, 38].
14. Discussion
We have reviewed two cases of FSGS associated with
signiﬁcant elevations in urinary OTA excretion following
inhalational exposure in water-damaged buildings. The
nephrotoxicity of OTA is undisputed in the literature in both
extensive animal studies and more limited human studies.
The precise role, if any, ochratoxin plays in the onset and
progression of FSGS in select individuals has yet to be
elucidated.
The etiology of FSGS is generally unknown, while treat-
ments are most often directed towards slowing progression.
At least in the case of drug toxicity including heroin and
other drugs, toxins have been acknowledged to play an
important role in some cases of FSGS. Undoubtedly, like
most human illnesses, it will involve a complex interaction of
environmental exposures with underlying genetics. Further
study is clearly indicated; however, in the interim, it is wise
to test for and initiate appropriate, safe measures to lower
the body burden of OTA. As has been discussed, a toxin
as potent as OTA that is known to be found in the highest
concentrations in kidney tissue could certainly play a role in
the onset and progression of the disease. A kidney already
damaged from any cause would be all the more negatively
aﬀected by the strain of excreting a potent nephrotoxin.
It is the recommendation of the authors to obtain a
detailed environmental history including exposure to water-
damaged indoor environments and a dietary history in the
case of primary idiopathic FSGS as well as other kidney
disease of unclear etiology. If the history is remarkable for
any potential exposures to OTA and perhaps even if it is
not, we would urge evaluation for the presence of OTA
in urine. If biopsy samples are available, it would also be
useful to test these tissues since elevated levels in the kidney,
might support the removal of diseased kidneys at the time
of transplantation as opposed to the common practice of
leaving them in place. In light of the detection of OTA in
individuals with chronic fungal sinusitis [33], testing of nasal
secretions for OTA and other mycotoxins should also be
considered.
Additionally, consideration should be given to the testing
of breast milk for OTA and other mycotoxins in mothers
exposedtowater-damagedenvironmentsasthedataisstrong
that OTA can be excreted in breast milk and that the
consequences of this exposure can be signiﬁcant especially
given the increased susceptibility of the neonate to toxins.
Forexample, ratneonatesexposed toOTAin onlylactational
milk had a 4 to 5 times higher level of OTA compared
with those rats exposed only via the placenta [60]. Results
of a recent biomonitoring study in Chile conﬁrmed the
p r e s e n c eo fO T Ai nb r e a s tm i l ka tl e v e l ss u c ht h a tt h e
tolerable daily intake could be exceeded [75]. Of concern,
in 50 lactating mothers and their infants in Egypt, the
presence of OTA was associated with signiﬁcantly higher
levels of urine microglobulin and microalbuminuria in the
infants consistent with early renal injury [76]. Moreover,
the level of OTA in the infants sera correlated with the
degree of microalbuminuria [76], raising great concern
about maternal transfer of OTA and injury to the infants.
If elevated levels of urinary OTA are found, there are
a number of safe treatments that should be considered
to lower the body burden of this mycotoxin. The most
important are the avoidance of further exposure and the useJournal of Environmental and Public Health 7
of the bile acid resin binding agent, cholestyramine, to de-
crease enterohepatic recirculation of OTA. Studies have
shown that animals fed a diet of OTA plus cholestyramine
had a signiﬁcant shift of OTA from the plasma and urine
to the stool, where it is presumably excreted bound to
cholestyramine [74]. This will safely reduce the burden on
the kidneys as cholestyramine is not absorbed systemically
and remains in the gastrointestinal tract. Side eﬀects, which
are primarily limited to the gastrointestinal tract, must be
consideredaswellasthetimingofcholestyramineawayfrom
medications and vitamins, primarily fat soluble vitamins.
Many patients tolerate the pure resin better than the com-
mercial prescription prepared with sugar, artiﬁcial colors,
and a number of additives. As a number of patients with
kidney disease also have hyperlipidemia, cholestyramine
could potentially beneﬁcial for its lipid lowering eﬀect.
Other potential sequestrant treatments include the use
of charcoal which is included in the military textbook
recommendations for exposure to trichothecene mycotoxins
which has been associated with Yellow Rain exposure [77].
Clay and zeolite have been studied for their eﬃcacy of
mycotoxin binding in animals [78, 79] and likely have a use
in human illness caused by mycotoxins including OTA.
The use of licorice extract and melatonin was mentioned
earlier in this paper and require further study, but may
oﬀer a safe option for reducing the toxicity of ochratoxin.
There is some evidence that sauna shifts the excretion of
ochratoxin to sweat; however, use of sauna needs to be very
carefully monitored, especially on initiation. Antioxidants,
including glutathione, are also likely to be helpful for their
antioxidant and detoxiﬁcation eﬀects [23]. Vitamins A, C,
E and selenium are other potentially beneﬁcial antioxidants
that may be protective in their role as superoxide anion
scavengers [22, 75].
As we learn more about genomic studies, including the
evaluation of cytochrome p450 and glutathione (GSTP and
GSTM) pathways, it may be possible to identify those who
m a yb em o s tv u l n e r a b l et oi l l n e s sa f t e re x p o s u r et oo c h r a -
toxin and other toxic agents and having this information
could be invaluable in directing appropriate therapies and
medication use in the future.
Given the important metabolism of OTA that occurs in
the gut, and evidence of increased toxicity when gut ﬂora is
disturbed with an antibiotic, it would pay to direct attention
toward achieving and maintaining healthy gastrointestinal
functioning. In fact, there is evidence that some beneﬁcial
gastrointestinal ﬂora can have positive eﬀects on decreasing
toxicity from OTA including speciﬁc strains of yeast [80].
Interestingly, aspartame has been found to decrease toxicity
of OTA through a phenylalanine-mediated mechanism [38];
however, there may be some concerns about other potential
toxicities associated with aspartame.
Most importantly, anyone with chronic illness should
carefully evaluate their environment and other sources of
potential toxic exposures and make every eﬀort to control
these exposures. Unfortunately, in the case of exposures to
mycotoxins including ochratoxin, it is imperative to address
issues of cross contamination of items exposed to water-
damaged/mold contaminated environment. Mycotoxins are
very diﬃcult to destroy and travel readily on ﬁne, often
submicron-sized particles making simple spore testing inad-
equate for determining the presence of mycotoxins. Thus,
a thorough approach is needed to address contamination
of items exposed to water-damaged environments to avoid
continued exposure to mycotoxins including ochratoxin
through these items even if the building is no longer a source
of exposure.
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